Swiss peptide and oligonucleotide specialist Bachem has agreed to buy an undeveloped site in Sisslerfeld from DSM. It has completed the purchase of a first plot, with...
Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has announced the signing of two major contracts for supplying large volumes of...
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this...
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding...
19.09.2018
- Natural products have been used since thousands of years for the treatment of a wide range of medical conditions in the form of traditional medicines. Today 60% of all new small...
Swiss biochemicals company Bachem announced that Dr. Anne-Kathrin Stoller will succeed Dr. José de Chastonay as Chief Marketing Officer of the organization on January 1...
13.04.2017
- US drugmaker Janssen Pharmaceuticals has entered into a collaboration with Japanese biopharma PeptiDream. The deal, which gives Janssen access to PeptiDream’s peptide discovery...
